A niche issuer launches a biotech ETF whose core holdings include companies benefiting from the GLP-1 weight-loss drug craze. The Tema Cardiovascular and Metabolic ETF (ticker: HRTS) tracks companies involved in the treatment of cardio-metabolic diseases, i.e. cardiovascular disease, obesity and diabetes, such as Novo Nordisk, Eli Lilly or AstraZeneca. 
(MT Newswires)

Bloomberg videos